Results 261 to 270 of about 575,729 (357)

Local and Systemic Effects of Chronic Intracavernous Injection of Papaverine, Prostaglandine E1 and Saline in Primates [PDF]

, 1989
Aboseif, Sherif R., Bosch, Ruud J. L. H., Breza, J., Bénard, Francois, Lue, Tom F., Stackl, W., Stief, Christian Georg, Tanagho, Emil A.   +7 more
core  

Carbonic Anhydrase IX-Targeted Molecular Probe for Positron Emission Tomography Imaging of Clear Cell Renal Cell Carcinoma

Bingqing Qiu, Qianhui Wang, Huan Peng, Zhiqing Yang, Zhu Zhiyu, Ling Qiu, Jianguo Lin   +6 more
openalex   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

CT-based AI score associates with perioperative outcomes in nephron-sparing surgery for renal cell carcinoma. [PDF]

Cancer Imaging
Shengfa L, Liqing S, Shu C, Huijian C, Yuying L, Zijie L, Yinfeng X, Qianwen L, Zhuting F, Mingping M, Minxiong H.   +10 more
europepmc   +1 more source

Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma

, 2015
Е. А. Ворошилова, Dmitry Nosov, А. В. Карпухин, И. Н. Соколова, М. Yu. Fedyanin   +4 more
openalex   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Microfluidics and molecular diagnostics in renal cell carcinoma: advances, challenges, and future directions. [PDF]

Front Oncol
Abu-Dawas SB, Alwadi AY, Farahat YH, Abu-Dawas RB, Quraiba LN, Abu-Omar RA, AlKattan K, Khan MI, Yaqinuddin A.   +8 more
europepmc   +1 more source

Table S1 from Dietary Fish and n-3 Polyunsaturated Fatty Acid Consumption, and Renal Cell Carcinoma Risk in Japan: The Japan Public Health Center-Based Prospective Study

Michiko Takahashi, Tomotaka Sobue, Ling Zha, Tetsuhisa Kitamura, Motoki Iwasaki, Manami Inoue, Taiki Yamaji, Shoichiro Tsugane, Norie Sawada   +8 more
openalex   +1 more source

Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort [PDF]

Goran Benčina, Rolf Billeskov, Rasmine Bak, Ahmed Abduljabar Al-Sabbagh, Julie Højgaard Pedersen, Marina Lunetcas, Emma Heeno, Sara Tolouee, Tuba Ashraf, Niels Fristrup, Nessn Azawi   +10 more
openalex   +1 more source

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

British Journal of Clinical Pharmacology, EarlyView.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton, Nielka P. van Erp, Annenienke C. van de Ven, Janneke E. W. Walraven, Loek A. W. de Jong   +4 more
wiley   +1 more source